NCT06701526已完成4 期
Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 164
- 试验地点
- 65
- 主要终点
- Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Scale
研究概览
简要总结
The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant has a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders 3rd Edition (ICHD-3) guidelines with a history of migraine of at least 12 months prior to the Screening Visit.
- •The participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit.
- •The participant has documented evidence of recent inadequate response to either one anti-CGRP monoclonal antibody (mAb) (other than eptinezumab) or one gepant, indicated and used for migraine prevention.
排除标准
- •The participant has taken more than 10 tablets of ubrogepant or more than 8 tablets of rimegepant per month as an acute migraine medication in the 1 month prior to the screening visit and during the 4-week baseline period.
- •The participant has previously had an inadequate response to more than one CGRP-targeting therapy (anti-CGRP mAb or gepants), indicated for migraine prevention.
- •The participant has a history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin or adequately treated cervical intraepithelial neoplasia, that has not been in remission for >5 years prior to the first dose of eptinezumab. Male participants with abnormal prostate-specific antigen levels according to national/local guideline may be enrolled in the trial provided they have been followed up, have been asymptomatic, and have had no treatment for prostate cancer. Participants under surveillance for a low and stable level of M-component are allowed.
- •The participant has previously been treated with eptinezumab.
- •Other protocol-defined inclusion and exclusion criteria apply.
研究组 & 干预措施
Eptinezumab
Experimental
Participants will receive eptinezumab at Baseline (Day 1) and Week 12
干预措施: Eptinezumab (Drug)
结局指标
主要结局
Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Patient Global Impression of Change (PGIC) Scale
时间窗: Week 24
次要结局
- Change from Baseline in Monthly Headache Days (MHDs)(Weeks 1-12 and 13-24)
- Change from Baseline in Monthly Migraine Days (MMDs)(Weeks 1-12 and 13-24)
- Change from Baseline in MMDs with Use of Acute Medication(Weeks 1-12 and 13-24)
- Change from Baseline in Migraine Disability Assessment (MIDAS) Scores(Weeks 12 and 24)
- Goal Attainment Scaling (GAS) Score(Weeks 12 and 24)
- Change from Baseline in the Percentage of MMDs with Severe Pain Intensity(Weeks 1-12 and 13-24)
- Number of Participants with Response of "Much Improved" or "Very Much Improved" on the PGIC Scale(Week 12)
- PGIC Score(Weeks 12 and 24)
- Number of Participants with GAS Score ≥50(Weeks 12 and 24)
- Change from Baseline in Number of Good Days per Month(Weeks 12 and 24)
- Change from Baseline in Migraine Clinical Outcome Assessment System-Cognition (MiCOAS-COG) Score(Weeks 12 and 24)
- Number of Participants with Response of "Much Improved" or "Very Much Improved" in Brain Fog(Weeks 12 and 24)
- Brain Fog Score(Weeks 12 and 24)
- Number of Participants with Adverse Events (AEs)(Up to Week 26)
- CGIC Score(Weeks 12 and 24)
- Number of Participants with Response of "Much Improved" or "Very Much Improved" on the Clinical Global Impression of Change (CGIC) Scale(Weeks 12 and 24)
研究者
研究点 (65)
Loading locations...
相似试验
已完成
3 期
Eptinezumab in Adults With Migraine and Medication Overuse HeadacheMigraineMedication Overuse HeadacheNCT04772742H. Lundbeck A/S193
已完成
1 期
A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell LinesHealthy ParticipantsNCT05074459H. Lundbeck A/S84
招募中
3 期
A Study of Eptinezumab in Pediatric Participants With Episodic MigraineEpisodic MigraineNCT05897320H. Lundbeck A/S315
已完成
2 期
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in AdultsMigraineNCT06728553Manistee Therapeutics78
已完成
4 期
Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45Menstrually Related MigraineMigraineMenstrual MigraineNCT06173661Brigham and Women's Hospital15